Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic.
Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic.
Eur J Pharmacol. 2021 Jan 08;:173854
Authors: Noreen S, Maqbool I, Madni A
Abstract
The current outbreak of novel COVID-19 challenges the development of an efficient treatment plan as soon as possible. Several promising treatment options stand out as potential therapy of COVID-19, including plasma-derived drugs, monoclonal antibodies, antivirals, antimalarial, cell therapy, and corticosteroids. Dexamethasone an approved corticosteroid medication, acting as an anti-inflammatory and immunosuppressant agent. In the current pandemic, dexamethasone is declared a "major development" in the fight against COVID-19. Steroidal dexamethasone was presented as the recent advancement that significantly reduces the mortality rate among severe COVID-19 cases. This review summarizes the preliminary opinion about the dexamethasone outbreak, therapeutic potential, risks, and strategies during the COVID-19 pandemic.
PMID: 33428898 [PubMed - as supplied by publisher]
Source: European Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Noreen S, Maqbool I, Madni A Tags: Eur J Pharmacol Source Type: research
More News: Corticosteroid Therapy | COVID-19 | Dexamethasone | Drugs & Pharmacology | Outbreaks | Pandemics | Science